Vaxfectin-formulated H1N1 vaccine: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in about 30 healthy adult volunteers showed that 2 doses of Vical's Vaxfectin-formulated H1N1 vaccine given on days 0 and 21 were well tolerated....